DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer

被引：0

作者：

Board, Ruth E. ^{[1
]}

Knight, Lucy ^{[2
]}

Greystoke, Alastair ^{[1
]}

Blackhall, Fiona H. ^{[3
]}

Hughes, Andrew ^{[4
]}

Dive, Caroline ^{[5
]}

Ranson, Malcolm ^{[6
]}

机构：

[1] Paterson Inst Canc Res, Clin & Expt Pharmacol, Wilmslow Rd, Manchester M20 4BX, Lancs, England

[2] AstraZeneca, Discovery Med, Macclesfield SK10 4TG, Cheshire, England

[3] Christie Hosp NHS Trust, CRUK Dept Med Oncol, Manchester M20 4BX, Lancs, England

[4] AstraZeneca, Discovery Med, Macclesfield SK10 4TG, Cheshire, England

[5] Paterson Inst Canc Res, Clin & Expt Pharmacol, Manchester M20 4BX, Lancs, England

[6] Christie Hosp NHS Trust, CRUK Dept Med Oncol, Manchester M20 4BX, Lancs, England

来源：

BIOMARKER INSIGHTS | 2007年 / 2卷

关键词：

DNA methylation; biomarker; circulating tumour DNA; MSP; MethyLight;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Free circulating DNA, which is thought to be derived from the primary tumour, can be detected in the blood of patients with cancer. Detection of genetic and epigenetic alteration in this tumour DNA offers a potential source of development of prognostic and predictive biomarkers for cancer. One such change is DNA methylation of the promotor region of tumour suppressor genes. This causes down regulation of tumour suppressor gene expression, a frequent event in carcinogenesis. Hypermethylation of the promotor region of a number of genes has been detected in many tumour types and more recently these changes have been detected in circulating tumour DNA. This review will summarise the literature detailing DNA methylation in circulating tumour DNA and discuss some of the current controversies and technical challenges facing its use as a potential biomarker for cancer.

引用

页码：307 / 319

页数：13

共 50 条

[41] DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer
Leygo, Catherine
Williams, Marissa
Jin, Hong Chuan
Chan, Michael W. Y.
Chu, Wai Kit
Grusch, Michael
Cheng, Yuen Yee
DISEASE MARKERS, 2017, 2017
[42] Monitoring gastric cancer progression with circulating tumour DNA
T Hamakawa
Y Kukita
Y Kurokawa
Y Miyazaki
T Takahashi
M Yamasaki
H Miyata
K Nakajima
K Taniguchi
S Takiguchi
M Mori
Y Doki
K Kato
British Journal of Cancer, 2015, 112 : 352 - 356
[43] Monitoring gastric cancer progression with circulating tumour DNA
Hamakawa, T.
Kukita, Y.
Kurokawa, Y.
Miyazaki, Y.
Takahashi, T.
Yamasaki, M.
Miyata, H.
Nakajima, K.
Taniguchi, K.
Takiguchi, S.
Mori, M.
Doki, Y.
Kato, K.
BRITISH JOURNAL OF CANCER, 2015, 112 (02) : 352 - 356
[44] Clinical application of circulating tumour DNA in colorectal cancer
Loft, Matthew
To, Yat Hang
Gibbs, Peter
Tie, Jeanne
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (09): : 837 - 852
[45] Clinical relevance of circulating tumour DNA in colorectal cancer
Kong, Joseph Cherng
Prabhakaran, Swetha
Tie, Jeanne
Ramsay, Rob
Heriot, Alexander
Warrier, Satish
ANZ JOURNAL OF SURGERY, 2021, 91 (05) : 774 - 775
[46] Landscape of circulating tumour DNA in metastatic breast cancer
Davis, Andrew A.
Jacob, Saya
Gerratana, Lorenzo
Shah, Ami N.
Wehbe, Firas
Katam, Neelima
Zhang, Qiang
Flaum, Lisa
Siziopikou, Kalliopi P.
Platanias, Leonidas C.
Gradishar, William J.
Behdad, Amir
Cristofanilli, Massimo
EBIOMEDICINE, 2020, 58
[47] Detection of circulating tumour DNA in the blood of cancer patients
Hainaut, P
M S-MEDECINE SCIENCES, 2000, 16 (03): : 446 - 446
[48] Subtype specific DNA methylation in circulating DNA of metastatic breast cancer patients
Uehiro, N.
Sato, F.
Saji, S.
Toi, M.
BREAST, 2015, 24 : S42 - S42
[49] Circulating mitochondrial DNA as a biomarker for lung cancer screening
von Itzstein, Mitchell S.
Gerber, David E.
Minna, John D.
TRANSLATIONAL LUNG CANCER RESEARCH, 2022, : 1522 - 1525
[50] Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?
Leung, Felix
Kulasingam, Vathany
Diamandis, Eleftherios P.
Hoon, Dave S. B.
Kinzler, Kenneth
Pantel, Klaus
Alix-Panabieres, Catherine
CLINICAL CHEMISTRY, 2016, 62 (08) : 1054 - 1060

← 1 2 3 4 5 →